Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A 6-year follow-up of the NATALEE trial confirms that adding ribociclib to standard hormone therapy improves overall survival in HR+/HER2-negative early breast cancer — and the benefit holds even after patients stop taking the drug. At 6 years, overall survival was 91.9% with the combo vs. 89.7% with hormone therapy alone. The findings, presented at ESMO 2026, strengthen the case for adjuvant CDK4/6 inhibition in this common breast cancer subtype.
The long game pays off for ribociclib in early breast cancer
Six years of follow-up data from the NATALEE phase 3 trial — presented at ESMO 2026 and published in Annals of Oncology — confirm that adding ribociclib to a nonsteroidal aromatase inhibitor (NSAI) meaningfully improves survival in HR+/HER2-negative early breast cancer. Crucially, the survival benefit persisted even though patients had been off ribociclib for a median of over 3 years by the time of this analysis.
The trial used a lower ribociclib dose (400 mg vs. the 600 mg approved for advanced disease) to improve tolerability, and a longer 3-year treatment duration to drive more tumor cells into irreversible senescence — a deliberate design choice that appears to be paying dividends.
By the Numbers
Why it matters: HR+/HER2-negative breast cancer is the most common breast cancer subtype globally. These results — showing durable survival gains even after the drug is stopped — support broader use of adjuvant ribociclib and could influence treatment guidelines for a large patient population.
